United BioPharma, Inc. develops, manufactures, and markets monoclonal antibody (mAb) products and biosimilar antibodies in Taiwan. Its molecules product pipeline includes UB-421 for the treatment of AIDS; UB-621, an anti-herpes simplex virus mAb; UB-221, which is in phase I trial for the treatment of Chronic urticaria; UB-721 that is in process development for the treatment of autoimmune diseases; UB-923 that is in manufacturing process development for the treatment of non-hodgkin’s lymphoma, rheumatoid arthritis, etc.; UB-925, which is in process development stage for the treatment of gastric, colorectal, and non-small cell lung cancer; and UB-926 that is in process development stage for the treatment of breast cancer. The company’s biosimilars under development also comprise UB-921, which is in Phase I clinical trial for the treatment of breast cancer; and UB-922, which is in process development for the treatment of colorectal, brain, renal cell, and non-small cell cancers. It has a collaboration agreement with Shanghai Public Health Clinical Centre and Cheng Kung University's Department of Microbiology and Immunology for long-acting herpes treatment UB-621. United BioPharma, Inc. was founded in 2013 and is based in Taipei, Taiwan.